Photo of Valerie Gouon-Evans

Valerie Gouon-Evans

  • ASSISTANT PROFESSOR Developmental and Regenerative Biology
  • ASSISTANT PROFESSOR Medicine, Liver Diseases
Print ProfilePrint Profile

Biography

Research

From Liver Development to Cell Therapy for Liver Diseases

 
The Gouon-Evans lab is interested in understanding the liver development and regeneration in mice and human using pluripotent stem cells as a model system and cellular source for liver cell therapy.

 

Projects currently developed in the lab:

 

Understanding early hepatic specification of the endoderm in the mouse: crosstalk between endoderm and endothelial cells

Studies in animal models have shown that complex cell-cell interactions are required for hepatic specification and maturation during liver development. Namely, endothelial cells are observed very early around the hepatic endoderm, and in their absence the hepatic endoderm does not expand to form the liver bud. The relevance of the endoderm-endothelial cell interactions is not understood. Using the mouse embryonic stem (ES) cell differentiation system as well as the early mouse embryo, we recently demonstrated that the endothelial cell niche induces hepatic specification through dual repression of Wnt and Notch signaling. Ongoing studies aim at revealing further pathways involved in the endothelial cells – endoderm crosstalk required for hepatic specification.

 

Directed differentiation of pluripotent stem cells toward functional mouse and human hepatocytes for cell Therapy in liver diseases

The use of ES or induced pluripotent stem (iPS) cell differentiation cultures to generate functional hepatic cells for cell therapy of liver diseases is still an ongoing challenge. Even though a growing literature has established efficient protocols to generate such cells in vitro, the pluripotent stem cell-derived hepatic cells remain inefficient at repopulating diseased livers. Our research is focused on identifying and modulating the molecular pathways required for successful liver regeneration following hepatic cell transplantation into a liver deficient mouse model.

For more information, please visit the Gouon-Evans Laboratory website.


The Gouon-Evans Lab is part of the Black Family Stem Cell Institute, the Departments of Developmental and Regenerative Biology and Medicine, Division of Liver Diseases.

Dr Gouon-Evans is a PF Applicant for the Mount Sinai Alcoholic Liver Diseases Research Center and for the Experimental Therapeutics Institute.

Publications

Han S, Dziedzic N, Gadue P, Keller GM, Gouon-Evans V. An endothelial cell niche induces hepatic specification through dual repression of wnt and notch signaling. Stem cells (Dayton, Ohio) 2011 Feb; 29(2).

Christodoulou C, Longmire TA, Shen SS, Bourdon A, Sommer CA, Gadue P, Spira A, Gouon-Evans V, Murphy GJ, Mostoslavsky G, Kotton DN. Mouse ES and iPS cells can form similar definitive endoderm despite differences in imprinted genes. The Journal of clinical investigation 2011 Jun; 121(6).

Green MD, Chen A, Nostro MC, d'Souza SL, Schaniel C, Lemischka IR, Gouon-Evans V, Keller G, Snoeck HW. Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells. Nature biotechnology 2011 Mar; 29(3).

Zhao X, Monson C, Gao C, Gouon-Evans V, Matsumoto N, Sadler KC, Friedman SL. Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells. Developmental biology 2010 Aug; 344(1).

Gadue P, Gouon-Evans V, Cheng X, Wandzioch E, Zaret KS, Grompe M, Streeter PR, Keller GM. Generation of monoclonal antibodies specific for cell surface molecules expressed on early mouse endoderm. Stem cells (Dayton, Ohio) 2009 Sep; 27(9).

Gouon-Evans V, Boussemart L, Gadue P, Nierhoff D, Koehler CI, Kubo A, Shafritz DA, Keller G. BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nature biotechnology 2006 Nov; 24(11).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Gouon-Evans did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Atran Berg Laboratory Building Floor 7th floor Room 10F
1428 Madison Avenue
New York, NY 10029

Tel: 212-241-4033
Fax: 646-537-9695